1-17 of 17
Farhad Ravandi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Irene Ganan-Gomez, Tapan M. Kadia, Gautam Borthakur, Courtney D. DiNardo, Naval G. Daver, Elias J. Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1319–1326.
https://doi.org/10.1158/1078-0432.CCR-23-2860
Published: 01 April 2024
View article titled, Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Open the PDF for Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax in another window
Includes: Supplementary data
Journal Articles

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Jayastu Senapati, Warren C. Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Courtney D. DiNardo, Elias Jabbour, Jan Burger, Nicholas J. Short, Yesid Alvarado, Nitin Jain, Lucia Masarova, Ghayas C. Issa, Wei Qiao, Joseph D. Khoury, Sherry Pierce, Darla Miller, Koji Sasaki, Marina Konopleva, Kapil N. Bhalla, Gautam Borthakur, Naveen Pemmaraju
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4352–4360.
https://doi.org/10.1158/1078-0432.CCR-23-1429
Published: 01 November 2023
View article titled, Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Open the PDF for Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies in another window
Includes: Supplementary data
Journal Articles

Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)

Koichi Takahashi, Feng Wang, Kiyomi Morita, Keyur Patel, Carlos Bueso-Ramos, Abdallah Abou Zahr, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Jianhua Zhang, Xingzhi Song, Marisela Mendoza, Chang-Jiu Wu, Steven Kornblau, Courtney DiNardo, Guillermo Garcia-Manero, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop Kantarjian, Jorge Cortes, Marina Konopleva, Andrew Futreal
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 16.
https://doi.org/10.1158/1557-3265.HEMMAL17-16
Published: 14 December 2017
View article titled, Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)
Journal Articles

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

Lina Han, Jeffrey L. Jorgensen, Chris Brooks, Ce Shi, Qi Zhang, Graciela M. Nogueras González, Antonio Cavazos, Rongqing Pan, Hong Mu, Sa A. Wang, Jin Zhou, Gheath AI-Atrash, Stefan O. Ciurea, Mike Rettig, John F. DiPersio, Jorge Cortes, Xuelin Huang, Hagop M. Kantarjian, Michael Andreeff, Farhad Ravandi, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3385–3395.
https://doi.org/10.1158/1078-0432.CCR-16-1904
Published: 02 July 2017
View article titled, Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Open the PDF for Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract B22: Genome-wide methylation analysis reveals an independently validated CpG island methylator phenotype associated with favorable prognosis in acute myeloid leukemia.

Andrew D. Kelly, Heike Kroeger, Jumpei Yamazaki, Rodolphe Taby, Frank Neumann, Justin T. Lee, Rong He, Shoudan Liang, Yue Lu, Matteo Cesaroni, Sherry A. Pierce, Steven M. Kornblau, Carlos E. Bueso-Ramos, Farhad Ravandi, Hagop M. Kantarjian, Jean-Pierre J. Issa, Jaroslav Jelinek
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): B22.
https://doi.org/10.1158/1557-3265.HEMMAL14-B22
Published: 19 August 2015
View article titled, Abstract B22: Genome-wide methylation analysis reveals an independently validated CpG island methylator phenotype associated with favorable prognosis in acute myeloid leukemia.
Journal Articles

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, Yanis Boumber, Hagop Kantarjian, Farhad Ravandi, Jorge Cortes, Michael E. Rytting, Jitesh D. Kawedia, Jordan Basnett, Kirk S. Culotta, Zhihong Zeng, Hongbo Lu, Mary Ann Richie, Rebecca Garris, Lianchun Xiao, Wenbin Liu, Keith A. Baggerly, Elias Jabbour, Susan O'Brien, Jan Burger, Linda J. Bendall, Deborah Thomas, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-14-2888
Published: 14 June 2015
View article titled, A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Open the PDF for A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies

Weiguo Zhang, Chen Gao, Marina Konopleva, Ye Chen, Rodrigo O. Jacamo, Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi, Abhijit Ramachandran, Michael Andreeff
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2363–2374.
https://doi.org/10.1158/1078-0432.CCR-13-2052
Published: 30 April 2014
View article titled, Reversal of Acquired Drug Resistance in <em>FLT3</em>-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Open the PDF for Reversal of Acquired Drug Resistance in <em>FLT3</em>-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies in another window
Includes: Supplementary data
Journal Articles

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

Hun Ju Lee, Naval Daver, Hagop M. Kantarjian, Srdan Verstovsek, Farhad Ravandi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 327–335.
https://doi.org/10.1158/1078-0432.CCR-12-2087
Published: 16 January 2013
View article titled, The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia
Open the PDF for The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia in another window
Journal Articles

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

Srdan Verstovsek, Ayalew Tefferi, Hagop Kantarjian, Taghi Manshouri, Raja Luthra, Animesh Pardanani, Alfonso Quintás-Cardama, Farhad Ravandi, Pat Ault, Carlos Bueso-Ramos, Jorge E. Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 368–373.
https://doi.org/10.1158/1078-0432.CCR-08-1302
Published: 31 December 2008
View article titled, Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
Open the PDF for Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia in another window
Journal Articles

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Aaron D. Schimmer, Susan O'Brien, Hagop Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis Giles, Andre Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel-Reid, Mark Berger, Jean Viallet, Gautam Borthakur
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8295–8301.
https://doi.org/10.1158/1078-0432.CCR-08-0999
Published: 15 December 2008
View article titled, A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Open the PDF for A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies in another window
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis Giles, Thomas Fischer, Jorge Cortes, Guillermo Garcia-Manero, Joachim Beck, Farhad Ravandi, Eric Masson, Patricia Rae, Glen Laird, Sunil Sharma, Hagop Kantarjian, Margaret Dugan, Maher Albitar, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4628–4635.
https://doi.org/10.1158/1078-0432.CCR-06-0511
Published: 09 August 2006
View article titled, A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia

Farhad Ravandi, Zeev Estrov
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 340–344.
https://doi.org/10.1158/1078-0432.CCR-05-1879
Published: 20 January 2006
View article titled, Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia
Open the PDF for Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies

Farhad Ravandi, Moshe Talpaz, Zeev Estrov
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (2): 535–550.
Published: 01 February 2003
View article titled, Modulation of Cellular Signaling Pathways: <subtitle>Prospects for Targeted Therapy in Hematological Malignancies</subtitle>
Open the PDF for Modulation of Cellular Signaling Pathways: <subtitle>Prospects for Targeted Therapy in Hematological Malignancies</subtitle> in another window
Journal Articles

Effect of Food on the Oral Bioavailability of UFT and Leucovorin in Cancer Patients

Bharat Damle, Farhad Ravandi, Sanjeev Kaul, Daryl Sonnichsen, Irene Ferreira, Donald Brooks, David Stewart, David Alberts, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (3): 517–523.
Published: 01 March 2001
View article titled, Effect of Food on the Oral Bioavailability of UFT and Leucovorin in Cancer Patients
Open the PDF for Effect of Food on the Oral Bioavailability of UFT and Leucovorin in Cancer Patients in another window
Journal Articles

A Phase I Study of Recombinant Interferon-β in Patients with Advanced Malignant Disease

Farhad Ravandi, Zeev Estrov, Razelle Kurzrock, James B. Breitmeyer, Birgit J. Maschek, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 3990–3998.
Published: 01 December 1999
View article titled, A Phase I Study of Recombinant Interferon-β in Patients with Advanced Malignant Disease
Open the PDF for A Phase I Study of Recombinant Interferon-β in Patients with Advanced Malignant Disease in another window